Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 34 Carcinoma, Hepatocellular 33 Carcinoma, Non-Small-Cell Lung 23 Colorectal Neoplasms 16 Esophageal Squamous Cell Carcinoma 12 Lung Neoplasms 9 Rectal Neoplasms 8 Nasopharyngeal Carcinoma 8 Esophageal Neoplasms 6 Cholangiocarcinoma 6 Squamous Cell Carcinoma of Head and Neck 5 Neoplasm Metastasis 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Small Cell Lung Carcinoma 4 Pancreatic Neoplasms 4 Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Renal Cell 4 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Extranodal NK-T-Cell 3 Carcinoma 3 Breast Neoplasms 3 Spinocerebellar Degenerations 2 Sarcoma 2 Recurrence 2 Nonsquamous Non-Small Cell Lung Cancer 2 Neuroendocrine Tumors 2 Lymphoma, T-Cell, Peripheral 2 Locally Advanced Rectal Cancer 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × sintilimab × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡